Thomas Paul, Ph.D., is a Senior Director of the Tumor Biology Group in the Pfizer Oncology R&D unit in La Jolla, CA. He leads a group focused on therapeutic targeting of oncogenic pathways in cancer through development of small molecule inhibitors. His group has progressed multiple compounds into clinical testing including PF-06821497 (EZH2 inhibitor/ Mevrometostat), PF-06939999 (PRMT5 inhibitor), and more recently PF-07258144 (KAT6 inhibitor/Prifetrastat). In addition, he helps lead several discovery initiatives within Pfizer, manages the postdoctoral program in Pfizer oncology, and has developed multiple academic and industry collaborations. Prior to joining Pfizer, Dr. Paul was a Scientist at Celgene in San Diego, CA (2009-2012) and was responsible for drug development activities for projects targeting epigenetic proteins including histone methyltransferases, histone demethylases, and histone readers. He received his BS degree in Biology from the University of North Carolina at Chapel Hill in 1998 and his PhD from Cornell University in 2005 studying biochemistry. He was a postdoctoral fellow at the National Cancer Institute in Bethesda, MD from 2005-2009 where he studied cancer epigenetics in acute myeloid leukemia.